These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 33519442)

  • 1. Ranolazine as an Alternative Therapy to Flecainide for SCN5A V411M Long QT Syndrome Type 3 Patients.
    Cano J; Zorio E; Mazzanti A; Arnau MÁ; Trenor B; Priori SG; Saiz J; Romero L
    Front Pharmacol; 2020; 11():580481. PubMed ID: 33519442
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Specific Therapy Based on the Genotype in a Malignant Form of Long QT3, Carrying the V411M Mutation.
    Blich M; Khoury A; Suleiman M; Lorber A; Gepstein L; Boulous M
    Int Heart J; 2019 Jul; 60(4):979-982. PubMed ID: 31257342
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ranolazine for Congenital Long-QT Syndrome Type III: Experimental and Long-Term Clinical Data.
    Chorin E; Hu D; Antzelevitch C; Hochstadt A; Belardinelli L; Zeltser D; Barajas-Martinez H; Rozovski U; Rosso R; Adler A; Benhorin J; Viskin S
    Circ Arrhythm Electrophysiol; 2016 Oct; 9(10):. PubMed ID: 27733495
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [High incidence of sudden cardiac death in one family with type-3 long QT syndrome: molecular genetics and electrophysiology mechanism analysis].
    Zhou H; Li Z; Ali Raza G; Zhu W; Zhou Q; Shen Y; Xie J; Cao Q; Wan R; Hu J; Hong K
    Zhonghua Xin Xue Guan Bing Za Zhi; 2015 Dec; 43(12):1046-50. PubMed ID: 26888838
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Normalization of ventricular repolarization with flecainide in long QT syndrome patients with SCN5A:DeltaKPQ mutation.
    Windle JR; Geletka RC; Moss AJ; Zareba W; Atkins DL
    Ann Noninvasive Electrocardiol; 2001 Apr; 6(2):153-8. PubMed ID: 11333173
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ranolazine for congenital and acquired late INa-linked arrhythmias: in silico pharmacological screening.
    Moreno JD; Yang PC; Bankston JR; Grandi E; Bers DM; Kass RS; Clancy CE
    Circ Res; 2013 Sep; 113(7):e50-e61. PubMed ID: 23897695
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tbx5 variants disrupt Nav1.5 function differently in patients diagnosed with Brugada or Long QT Syndrome.
    Nieto-Marín P; Tinaquero D; Utrilla RG; Cebrián J; González-Guerra A; Crespo-García T; Cámara-Checa A; Rubio-Alarcón M; Dago M; Alfayate S; Filgueiras-Rama D; Peinado R; López-Sendón JL; Jalife J; Tamargo J; Bernal JA; Caballero R; Delpón E;
    Cardiovasc Res; 2022 Mar; 118(4):1046-1060. PubMed ID: 33576403
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of sodium channel block with mexiletine to reverse action potential prolongation in in vitro models of the long term QT syndrome.
    Sicouri S; Antzelevitch D; Heilmann C; Antzelevitch C
    J Cardiovasc Electrophysiol; 1997 Nov; 8(11):1280-90. PubMed ID: 9395171
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The efficacy of Ranolazine on E1784K is altered by temperature and calcium.
    Abdelsayed M; Ruprai M; Ruben PC
    Sci Rep; 2018 Feb; 8(1):3643. PubMed ID: 29483621
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Flecainide, a therapeutic option in a patient with long QT syndrome type 3 caused by the heterozygous V411M mutation in the SCN5A gene.
    Carrasco JI; Izquierdo I; Medina P; Arnau MÁ; Salvador A; Zorio E
    Rev Esp Cardiol (Engl Ed); 2012 Nov; 65(11):1058-9. PubMed ID: 22721569
    [No Abstract]   [Full Text] [Related]  

  • 11. Delayed Ventricular Repolarization and Sodium Channel Current Modification in a Mouse Model of Rett Syndrome.
    Cheng H; Charles I; James AF; Abdala AP; Hancox JC
    Int J Mol Sci; 2022 May; 23(10):. PubMed ID: 35628543
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Subcutaneous and transvenous implantable cardioverter defibrillator in high-risk long-QT syndrome type 3 associated with Val411Met mutation in SCN5A.
    Yokoyama Y; Aiba T; Ueda N; Nakajima K; Kamakura T; Wada M; Yamagata K; Ishibashi K; Inoue Y; Miyamoto K; Nagase S; Noda T; Yasuda S; Shimizu W; Kusano K
    J Cardiol Cases; 2020 Nov; 22(5):238-241. PubMed ID: 33133318
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antagonism by ranolazine of the pro-arrhythmic effects of increasing late INa in guinea pig ventricular myocytes.
    Song Y; Shryock JC; Wu L; Belardinelli L
    J Cardiovasc Pharmacol; 2004 Aug; 44(2):192-9. PubMed ID: 15243300
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Further Insights in the Most Common SCN5A Mutation Causing Overlapping Phenotype of Long QT Syndrome, Brugada Syndrome, and Conduction Defect.
    Veltmann C; Barajas-Martinez H; Wolpert C; Borggrefe M; Schimpf R; Pfeiffer R; Cáceres G; Burashnikov E; Antzelevitch C; Hu D
    J Am Heart Assoc; 2016 Jul; 5(7):. PubMed ID: 27381756
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced late sodium current underlies pro-arrhythmic intracellular sodium and calcium dysregulation in murine sodium channelopathy.
    Rivaud MR; Baartscheer A; Verkerk AO; Beekman L; Rajamani S; Belardinelli L; Bezzina CR; Remme CA
    Int J Cardiol; 2018 Jul; 263():54-62. PubMed ID: 29754923
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In silico assessment of Y1795C and Y1795H SCN5A mutations: implication for inherited arrhythmogenic syndromes.
    Vecchietti S; Grandi E; Severi S; Rivolta I; Napolitano C; Priori SG; Cavalcanti S
    Am J Physiol Heart Circ Physiol; 2007 Jan; 292(1):H56-65. PubMed ID: 16980337
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Knock-in gain-of-function sodium channel mutation prolongs atrial action potentials and alters atrial vulnerability.
    Blana A; Kaese S; Fortmüller L; Laakmann S; Damke D; van Bragt K; Eckstein J; Piccini I; Kirchhefer U; Nattel S; Breithardt G; Carmeliet P; Carmeliet E; Schotten U; Verheule S; Kirchhof P; Fabritz L
    Heart Rhythm; 2010 Dec; 7(12):1862-9. PubMed ID: 20728579
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A mutation in the sodium channel is responsible for the association of long QT syndrome and familial atrial fibrillation.
    Benito B; Brugada R; Perich RM; Lizotte E; Cinca J; Mont L; Berruezo A; Tolosana JM; Freixa X; Brugada P; Brugada J
    Heart Rhythm; 2008 Oct; 5(10):1434-40. PubMed ID: 18929331
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanisms by which SCN5A mutation N1325S causes cardiac arrhythmias and sudden death in vivo.
    Tian XL; Yong SL; Wan X; Wu L; Chung MK; Tchou PJ; Rosenbaum DS; Van Wagoner DR; Kirsch GE; Wang Q
    Cardiovasc Res; 2004 Feb; 61(2):256-67. PubMed ID: 14736542
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of flecainide in patients with new SCN5A mutation: mutation-specific therapy for long-QT syndrome?
    Benhorin J; Taub R; Goldmit M; Kerem B; Kass RS; Windman I; Medina A
    Circulation; 2000 Apr; 101(14):1698-706. PubMed ID: 10758053
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.